·Î½Ãµ§°Ö(ÇǷνÃį) ROSIDEN GEL.[Piroxicam]
ÀϹÝÀǾàǰ | »èÁ¦
¾Ë¸²:
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù.
Àü¹®/ÀϹÝ
ÀϹÝ
¿¡Åº¿Ã ³¿»õ°¡ ³ª´Â Ȳ»ö Åõ¸íÇÑ °Ö »óÅÂÀÇ ¿¬°íÁ¦ÀÌ´Ù.
Á¦Á¶È¸»ç
½ÅdzÁ¦¾à(ÁÖ)
ÆÇ¸Åȸ»ç
½ÅdzÁ¦¾à(ÁÖ)
Çã°¡Á¤º¸
Á¤»ó
(1988.05.27)
BIT ¾àÈ¿ºÐ·ù
¿Ü¿ë ¼Ò¿°ÁøÅëÁ¦ (NSAIDs : Skin & Mucous Membrane)
º¹ÁöºÎºÐ·ù
264[ÁøÅ롤Áø¾ç¡¤¼ö·Å¡¤¼Ò¿°Á¦ ]
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå
648500500[A00302601] \0 ¿ø/1g(2016.10.01) (ÇöÀç¾à°¡) \55 ¿ø/1g(2014.02.01) (º¯°æÀü¾à°¡)
ATCÄÚµå
Piroxicam / M02AA07
NDCÄÚµå
[Proprietary Name Search _ ƯÇãµî·Ï¸í,»óÇ¥¸íÀ¸·Î °Ë»ö]
[Active Ingredient Search _ ÁÖ¼ººÐÀ¸·Î °Ë»ö]
[NDC Number Search _ NDCÄÚµå·Î °Ë»ö]
¼ººÐ / ÇÔ·®
[½ÉÆò¿ø ÁÖ¼ººÐÄÚµå ±âÁØ ¼ººÐÇÔ·®Á¤º¸ Á¶È¸]
÷°¡Á¦
º¥Áú¾ËÄÚ¿Ã ,
¿¡Åº¿Ã ,
Á¤Á¦¼ö ,
Ä«º¸¸Ó ,
Æ®·Ñ¾Æ¹Î ,
Æú¸®¼Ò¸£º£ÀÌÆ®20 ,
ÇÁ·ÎÇÊ·»±Û¸®ÄÝ ,
È÷µå·Ï½ÃÇÁ·ÎÇʼ¿·ê·Î¿À½º ,
D-¼Ò¸£ºñÅç¾× ,
L-¸àÅç
À¯·áȸ¿ø °áÀç½Ã ¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸ ¸¦
ÀÌ¿ë ÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·Ï Àº Àü¹®È¸¿ø À¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
Çã°¡Á¤º¸
Ç׸ñ
³»¿ë
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇѱݾ×
648500500[A00302601]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1g(2016.10.01) (ÇöÀç¾à°¡)
\55 ¿ø/1g(2014.02.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
[¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
ºü¸¥Á¶È¸
Á¦Ç°¼º»ó
¿¡Åº¿Ã ³¿»õ°¡ ³ª´Â Ȳ»ö Åõ¸íÇÑ °Ö »óÅÂÀÇ ¿¬°íÁ¦ÀÌ´Ù.
[Á¦ÇüÁ¤º¸ È®ÀÎ]
Æ÷À塤À¯Åë´ÜÀ§
10,20,30,60,100,200,450g
Æ÷À塤ÄÚµå´ÜÀ§
¾àǰ±Ô°Ý
´ÜÀ§
´ëÇ¥ÄÚµå
Ç¥ÁØÄÚµå
ºñ°í
20±×·¥
1 °³
8806485005002
8806485005071
¼öÃâ¿ë
60±×·¥
1 °³
8806485005002
8806485005064
¼öÃâ¿ë
10±×·¥
1 °³
8806485005002
8806485005057
¼öÃâ¿ë
5±×·¥
1 °³
8806485005002
8806485005040
ÁÖ¼ººÐÄÚµå
214003CCM
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
´ëÇ¥ÄÚµå
8806485005002
º¸°ü¹æ¹ý
±â¹Ð¿ë±â ½Ç¿Âº¸°ü.
¾à¸®ÀÛ¿ë
[Á¶È¸]
È¿´ÉÈ¿°ú
[ÀûÀÀÁõ º° °Ë»ö]
´ÙÀ½ Áúȯ ¹× Áõ»óÀÇ ÁøÅë¤ý¼Ò¿°(Ç׿°) : ÅðÇ༺°üÀý¿°(°ñ°üÀý¿°), ¾î±ú°üÀýÁÖÀ§¿°, °Ç¿°(ÈûÁÙ¿°)¤ý°ÇÃÊ¿°(ÈûÁÙÀ±È°¸·¿°), °ÇÁÖÀ§¿°, »ó¿Ï°ñ(À§ÆÈ»À)»ó°ú¿°(Å״Ͻº ¿¤º¸¿ì µî), ±ÙÀ°Åë(±Ù¿°, ±Ù¸·¿° µî), ¿Ü»óÈÄÀÇ Á¾Ã¢(ºÎ±â)¤ýµ¿Åë(ÅëÁõ)
¿ë¹ý¿ë·®
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¼ºÀÎ 1ȸ 1g(¾à 3cm), 1ÀÏ 3-4ȸ ȯºÎ(ÁúȯºÎÀ§)¿¡ ¹Ù¸£°í Àß ½º¸çµéµµ·Ï °¡º±°Ô ¹®Áö¸¥´Ù.
ÁÖ¿ä¾à¹° »óÈ£ÀÛ¿ë
[º¸±â]
±Ý±â
´ÙÀ½ ȯÀÚ´Â Åõ¿©ÇÏÁö ¸» °Í.
1) ÀÌ ¾à ¶Ç´Â ±âŸÀÇ ÇǷϽÃį Á¦Á¦¿¡ °ú¹ÎÁõÀÇ º´·ÂÀÌ Àִ ȯÀÚ
2) ¾Æ½ºÇǸ° õ½Ä(ºñ½ºÅ×·ÎÀ̵强 ¼Ò¿°(Ç׿°)ÁøÅëÁ¦ µî¿¡ ÀÇÇÑ Ãµ½Ä¹ßÀÛ À¯¹ß) ¶Ç´Â ±× º´·ÂÀÌ Àִ ȯÀÚ(ÁßÁõ(½ÉÇÑÁõ»ó) õ½Ä¹ßÀÛÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù)
3) ¾Æ½ºÇǸ° ¶Ç´Â ±âŸÀÇ ºñ½ºÅ×·ÎÀ̵强 ¼Ò¿°(Ç׿°)ÁøÅëÁ¦¿¡ µÎµå·¯±â, ºñ¿°(ÄÚ¿°) ¹× ¸Æ°üºÎÁ¾(Ç÷°üºÎ±â)À» ÀÏÀ¸Å² ȯÀÚ
4) 14¼¼ ÀÌÇÏÀÇ ¼Ò¾Æ
½ÅÁßÅõ¿©
´ÙÀ½ ȯÀÚ¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÒ °Í.
±â°üÁö õ½Ä ȯÀÚ(ÁßÁõ(½ÉÇÑÁõ»ó) õ½Ä¹ßÀÛÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù)
ÀÌ»ó¹ÝÀÀ
1) ÇǺΠ: ¶§¶§·Î ±¹¼ÒÀÇ °¡·Á¿ò, ¹ßÀû(ÃæÇ÷µÇ¾î ºÓ¾îÁü), ¹ßÁø, Àμ³(ºñ´Ã), ½ÀÁø¤ýÇǺο°, Á¢ÃËÇǺο°, È«¹Ý(ºÓÀº¹ÝÁ¡), µå¹°°Ô ±¤°ú¹ÎÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ÀÌ·¯ÇÑ Áõ»óÀÌ ½ÉÇÒ °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇÑ´Ù.
2) Àå±â°£ ¶Ç´Â °ú·®Åõ¿©½Ã Àü½ÅºÎÀÛ¿ëÀ¸·Î ±¸¿ª, À§Àå°ü ºÒÄè°¨, È£Èí°ï¶õ, ½ÅºÎÀü ¹× ½ÅÁõÈıº ȯÀÚ¿¡¼ÀÇ ±Þ¼º °£Áú¼º ½Å¿°(½ÅÀå¿°)ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
ÀϹÝÀû ÁÖÀÇ
1) ¼Ò¿°(Ç׿°)ÁøÅëÁ¦¿¡ ÀÇÇÑ Ä¡·á´Â ¿øÀοä¹ýÀÌ ¾Æ´Ñ ´ëÁõ¿ä¹ý(Áõ»óº°·Î Ä¡·áÇÏ´Â ¹æ¹ý)ÀÓ¿¡ À¯ÀÇÇÑ´Ù.
2) ÇǺΰ¨¿°ÁõÀ» ºÒÇö¼ºÈ(°ÑÀ¸·Î µå·¯³ªÁö ¾Ê°Ô) ½Ãų ¼ö ÀÖÀ¸¹Ç·Î °¨¿°À» ¼ö¹ÝÇÏ´Â ¿°Áõ¿¡ »ç¿ëÇÏ´Â °æ¿ì¿¡´Â ÀûÀýÇÑ Ç×±ÕÁ¦ ¶Ç´Â Ç×Áø±ÕÁ¦¸¦ º´¿ë(ÇÔ²² º¹¿ë(»ç¿ë))Çϰí ÃæºÐÈ÷ °üÂûÇÏ¿© ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
3) ¸¸¼ºÁúȯ(ÅðÇ༺°üÀý¿°(°ñ°üÀý¿°) µî)¿¡ »ç¿ëÇÏ´Â °æ¿ì¿¡´Â ¾à¹°¿ä¹ý ÀÌ¿ÜÀÇ ¿ä¹ýµµ °í·ÁÇÑ´Ù. ¶ÇÇÑ È¯ÀÚÀÇ »óŸ¦ ÃæºÐÈ÷ °üÂûÇÏ¿© ºÎÀÛ¿ë ¹ßÇö(µå·¯³¿)¿¡ À¯ÀÇÇÑ´Ù.
ÀӺο¡ ´ëÇÑ Åõ¿©
[ÀӺαݱ⠼ººÐ Á¶È¸]
1) ÀӽŠ3±â : ÇÁ·Î½ºÅ¸±Û¶õµò ÇÕ¼ºÀúÇØ·Î ÀÎÇØ Ãâ»êÀÌ Áö¿¬µÉ ¼ö ÀÖÀ¸¸ç Ãâ»ê½Ã ½ÇÇ÷, ½Å»ý¾Æ ÃâÇ÷, žÆÀÇ ½ÉÆóµ¶¼º(µ¿¸Æ°ü Á¶±âÆó¼â¸¦ ¼ö¹ÝÇÏ´Â Æó°íÇ÷¾Ð), ½Å±â´ÉÀúÇÏ·Î ¾ç¼ö°ú¼ÒÁõÀ» ¼ö¹ÝÇÏ´Â ½ÅºÎÀü µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ ½Ã±âÀÇ ÀӺο¡´Â »ç¿ëÇÏÁö ¾Ê´Â´Ù.
2) ÀӽŠ1±â ¹× 2±â : µ¿¹°ÀÇ »ý½Ä½ÇÇè °á°ú ÅÂÀÚµ¶¼ºÀº ¹ß»ýÇÏÁö ¾Ê¾ÒÀ¸³ª ÀӺο¡ ´ëÇÑ ¿¬±¸´Â ¾ÆÁ÷ ¹àÇôÁø ¹Ù ¾ø´Ù.
¼öÀ¯ºÎ¿¡ ´ëÇÑ Åõ¿©
ÇǷϽÃįÀ» °æ±¸ Åõ¿©ÇÑ ÈÄ Ç÷Áß ³óµµÀÇ ¾à 1%°¡ ¸ðÀ¯¿¡¼ ¹ß°ßµÇ¾ú´Ù. ¸ðÀ¯¿¡¼ÀÇ ÁÖ¼ººÐ ³óµµ¿Í ÀÓ»óÀû °ü·Ã¼ºÀº ¾ÆÁ÷ ¹àÇôÁø ¹Ù ¾øÀ¸³ª ¼öÀ¯ºÎ¿¡´Â Åõ¿©ÇÏÁö ¾Ê´Â´Ù.
¼Ò¾Æ¿¡ ´ëÇÑ Åõ¿©
¹Ì¼÷¾Æ, ½Å»ý¾Æ, ¿µ¾Æ(°«³¾Æ±â), À¯¾Æ ¹× ¼Ò¾Æ¿¡ ´ëÇÑ ¾ÈÀü¼ºÀÌ È®¸³µÇ¾î ÀÖÁö ¾Ê´Ù.
°í·ÉÀÚ¿¡ ´ëÇÑ Åõ¿©
°í·ÉÀÚ(³ëÀÎ)¿¡´Â ºÎÀÛ¿ëÀÇ ¹ßÇö(µå·¯³¿)¿¡ ƯÈ÷ ÁÖÀÇÇϰí ÇÊ¿äÇÑ ÃÖ¼ÒÇÑÀÇ Åõ¿©·Î ÇÑÁ¤ÇÏ´Â µî ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
Àû¿ë»óÀÇ ÁÖÀÇ
1) º´º¯(º´¿¡ ÀÇÇÑ ¸öÀÇ º¯È)ÀÌ ÀÖ´Â ÇǺÎ(ÃâÇ÷¼º ÇǺÎÁúȯ, ½ÀÁø, °¨¿°µÈ º´º¯(º´¿¡ ÀÇÇÑ ¸öÀÇ º¯È), È»ó, »óó), ´« ¹× Á¡¸·ºÎÀ§¿¡´Â »ç¿ëÇÏÁö ¾Ê´Â´Ù.
2) ¹ÐºÀºØ´ë¹ýÀ¸·Î »ç¿ëÇÏÁö ¾Ê´Â´Ù.
3) ÇǺο¡ ¼Õ»óÀÌ ÀÖÀ» °æ¿ì »ç¿ëÇϸé ÀϽÃÀûÀÎ Àڱذ¨À» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î »ç¿ë ½Ã ÁÖÀÇÇÑ´Ù.
º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ
±â¹Ð¿ë±â ½Ç¿Âº¸°ü.
Related FDA Approved Drug
Á¤º¸¿ä¾à
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
ÄÚµå ¹× ºÐ·ùÁ¤º¸
Ç׸ñ
³»¿ë
ÁÖ¼ººÐÄÚµå
214003CCM
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
´ëÇ¥ÄÚµå
8806485005002
BIT ¾àÈ¿ºÐ·ù
¿Ü¿ë ¼Ò¿°ÁøÅëÁ¦ (NSAIDs : Skin & Mucous Membrane)
ATC ÄÚµå
Piroxicam / M02AA07
[ÄÚµåºÐ·ù»ó¼¼¼³¸í]
[ATCÄÚµå¿¹Ãø]
º¹ÁöºÎºÐ·ùÄÚµå
264 (ÁøÅ롤Áø¾ç¡¤¼ö·Å¡¤¼Ò¿°Á¦ )
ÀǾàǰ ¹ÙÄÚµåÁ¤º¸
³»¿ëº¸±â
·Î½Ãµ§°Ö(ÇǷνÃį)(¼öÃâ¸í:SPPiroxicamGelSHINPOONGROSIDENGel) /
A00302601
Á¦Ç°±Ô°Ý:
30±×·¥ /Á¦Ç°¼ö·®:
1 /Á¦Çü:
°³
Æû¸ñ±âÁØÄÚµå:
198800043 /´ëÇ¥ÄÚµå:
8806485005002 /Ç¥ÁØÄÚµå:
8806485005019
±¸¹ÙÄÚµå:
8806103876250 /ºñ°í:-
·Î½Ãµ§°Ö(ÇǷνÃį)(¼öÃâ¸í:SPPiroxicamGelSHINPOONGROSIDENGel) /
A00302601
Á¦Ç°±Ô°Ý:
50±×·¥ /Á¦Ç°¼ö·®:
1 /Á¦Çü:
°³
Æû¸ñ±âÁØÄÚµå:
198800043 /´ëÇ¥ÄÚµå:
8806485005002 /Ç¥ÁØÄÚµå:
8806485005026
±¸¹ÙÄÚµå:
- /ºñ°í:-
·Î½Ãµ§°Ö(ÇǷνÃį)(¼öÃâ¸í:SPPiroxicamGelSHINPOONGROSIDENGel) /
A00302601
Á¦Ç°±Ô°Ý:
100±×·¥ /Á¦Ç°¼ö·®:
1 /Á¦Çü:
°³
Æû¸ñ±âÁØÄÚµå:
198800043 /´ëÇ¥ÄÚµå:
8806485005002 /Ç¥ÁØÄÚµå:
8806485005033
±¸¹ÙÄÚµå:
8806103876274 /ºñ°í:-
ÁÖ¼ººÐÄÚµå ºÐ¼® ¹× Áߺ¹Ã³¹æ °ËÅä
[ÁÖ¼ººÐÄÚµå ºÐ¼® ¹× Áߺ¹Ã³¹æ °ËÅä]
Drugs By Indication
[Àüüº¸±â]
Drugs By Classification
[Àüüº¸±â]
Á¦Ç°Á¤º¸
º¹¾àÁ¤º¸
Ç׸ñ
³»¿ë
LACTmed ¹Ù·Î°¡±â
[¹Ù·Î°¡±â]
¾à¸®ÀÛ¿ë
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
Ãà¾àº¹¾àÁöµµ
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
º¹¾àÁöµµ
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
ÀӺο¡´ëÇÑÅõ¿©
*
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
 
FDA : Dµî±Þ
(ÀӽŠ3±â ȤÀº Ãâ»êÀÌ °¡±î¿î ½ÃÁ¡¿¡ Åõ¿©µÉ °æ¿ì )
*
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
*
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
½ÅÀå¾Ö, °£Àå¾Ö½Ã ¿ë·®Á¶Àý
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
Pharmacokinetics
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
º¸°ü»ó ÁÖÀÇ
Á¶Á¦½Ã ÁÖÀÇ
½É»çÁ¤º¸
ÇмúÁ¤º¸
Ç׸ñ
³»¿ë
DUR (ÀǾàǰ»ç¿ëÆò°¡)
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
Mechanism of Action
Piroxicam¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ The antiinflammatory effect of Piroxicam may result from the reversible inhibition of cyclooxygenase, causing the peripheral inhibition of prostaglandin synthesis. The prostaglandins are produced by an enzyme called Cox-1. Piroxicam blocks the Cox-1 enzyme, resulting into the disruption of production of prostaglandins. Piroxicam also inhibits the migration of leukocytes into sites of inflammation and prevents the formation of thromboxane A2, an aggregating agent, by the platelets.
Pharmacology
Piroxicam¿¡ ´ëÇÑ Pharmacology Á¤º¸ Piroxicam is in a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). Piroxicam works by reducing hormones that cause inflammation and pain in the body. Piroxicam is used to reduce the pain, inflammation, and stiffness caused by rheumatoid arthritis and osteoarthritis.
Metabolism
Piroxicam¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
Half-life
Piroxicam¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 30 to 86 hours
Absorption
Piroxicam¿¡ ´ëÇÑ Absorption Á¤º¸ Well absorbed following oral administration.
Pharmacokinetics
PiroxicamÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
ÁøÅëÈ¿°ú ¹ßÇö½Ã°£ : °æ±¸ : 1½Ã°£ À̳»
ÃÖ´ëÈ¿°ú ¹ßÇö½Ã°£ : 3-5 ½Ã°£
´Ü¹é°áÇÕ : 99%
´ë»ç : °£´ë»ç
¹Ý°¨±â : 45-50 ½Ã°£
¼Ò½Ç : ¹Ìº¯Èü(5%) ¹× ´ë»çü·Î¼ ÁÖ·Î ´¢¸¦ ÅëÇØ, ¼Ò·®Àº ´ëº¯À¸·Î ¹è¼³µÊ
Biotransformation
Piroxicam¿¡ ´ëÇÑ Biotransformation Á¤º¸ Renal
Toxicity
Piroxicam¿¡ ´ëÇÑ Toxicity Á¤º¸ Symptoms of overdose include drowsiness, nausea, stomach pain, and/or vomiting.
Drug Interactions
Piroxicam¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Acebutolol Risk of inhibition of renal prostaglandinsAtenolol Risk of inhibition of renal prostaglandinsBetaxolol Risk of inhibition of renal prostaglandinsBevantolol Risk of inhibition of renal prostaglandinsBisoprolol Risk of inhibition of renal prostaglandinsCarteolol Risk of inhibition of renal prostaglandinsCarvedilol Risk of inhibition of renal prostaglandinsEsmolol Risk of inhibition of renal prostaglandinsLabetalol Risk of inhibition of renal prostaglandinsMetoprolol Risk of inhibition of renal prostaglandinsNadolol Risk of inhibition of renal prostaglandinsOxprenolol Risk of inhibition of renal prostaglandinsPenbutolol Risk of inhibition of renal prostaglandinsPindolol Risk of inhibition of renal prostaglandinsPractolol Risk of inhibition of renal prostaglandinsPropranolol Risk of inhibition of renal prostaglandinsSotalol Risk of inhibition of renal prostaglandinsTimolol Risk of inhibition of renal prostaglandinsRitonavir Ritonavir increases the toxicity of piroxicamWarfarin The NSAID increases the anticoagulant effectAcenocoumarol The NSAID increases the anticoagulant effectDicumarol The NSAID increases the anticoagulant effectAnisindione The NSAID increases the anticoagulant effectLithium The NSAID increases serum levels of lithiumMethotrexate The NSAID increases the effect and toxicity of methotrexateCyclosporine Monitor for nephrotoxicityAlendronate Increased risk of gastric toxicity
CYP450 Drug Interaction
[CYP450 TableÁ÷Á¢Á¶È¸] Piroxicam¿¡ ´ëÇÑ P450 table SUBSTRATES
CYP 2C9
NSAIDs:
diclofenac
ibuprofen
**piroxicam**
Oral Hypoglycemic Agents:
tolbutamide
glipizide
Angiotensin II Blockers:
NOT candesartan
irbesartan
losartan
NOT valsartan
celecoxib
fluvastatin naproxen
phenytoin
sulfamethoxazole
tamoxifen
tolbutamide
torsemide
warfarin
INHIBITORS
CYP 2C9
amiodarone
fluconazole
isoniazid
INDUCERS
CYP 2C9
rifampin
secobarbital
Food Interaction
Piroxicam¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take with food. Avoid alcohol.
Drug Target
[Drug Target]
Description
Piroxicam¿¡ ´ëÇÑ Description Á¤º¸ A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. [PubChem]
Dosage Form
÷°¡Á¦1 º¥Áú¾ËÄÚ¿Ã (ÁÖ»ç Á¦¿¡ ÇÑÇÔ.) ¡Û °æ°í
º¥Áú¾ËÄÚ¿ÃÀº ¹Ì¼÷¾Æ¿¡¼ Ä¡¸íÀûÀÎ °¡»Û È£ÈíÁõ»ó°ú ¿¬°üÀÌ ÀÖ´Â °ÍÀ¸·Î º¸°íµÇ¾ú´Ù.
¡Û ´ÙÀ½ ȯÀÚ¿¡´Â Åõ¿©ÇÏÁö ¸» °Í.
½Å»ý¾Æ, ¹Ì¼÷¾Æ(º¥Áú¾ËÄÚ¿ÃÀ» ÇÔÀ¯Çϰí ÀÖ´Ù.)
Drug Category
Piroxicam¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Inflammatory Agents, Non-SteroidalCyclooxygenase Inhibitors
Smiles String Canonical
Piroxicam¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CN1S(=O)(=O)C2=CC=CC=C2C(=O)C1=C(O)NC1=CC=CC=N1
Smiles String Isomeric
Piroxicam¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CN1S(=O)(=O)C2=CC=CC=C2C(=O)\C1=C(/O)NC1=CC=CC=N1
InChI Identifier
Piroxicam¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,20H,1H3,(H,16,17)/b15-13+/f/h17H
Chemical IUPAC Name
Piroxicam¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (3E)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxobenzo[e]thiazin-4-one
Drug-Induced Toxicity Related Proteins
PIROXICAM ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸Replated Protein :Glycogen synthaseDrug :piroxicam Toxicity :impairment into glycogen metabolism. liver unable to maintain glucose homeostasis. [¹Ù·Î°¡±â]
»ç¿ëÀÚÄÁÅÙÃ÷
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2023-06-06
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
¾Ë¸²
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.
°æ°í
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡± ¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â ·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù